Aditya P. Mohanty
CEO & DirectorMr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. Mr. Mohanty founded EnCellX, Inc., a functional cell selection company and he served as its Chief Executive Officer from December 2019 to November 2021. He served as the Co-Chief Executive Officer of BioTime, Inc.(now Lineage Cell Therapeutics, Inc ) from October 19, 2015 and its President since December 5, 2017 to September 17, 2018. Mr. Mohanty serves as a Member of Scientific Advisory Board at Cellect Biotechnology Ltd. since August 2020. Mr. Mohanty served as the Chief Operating Officer of BioTime, Inc. from December 29, 2014 to October 2015. He joined BioTime in December 2014 from Shire plc, where he served in a number of executive positions, including as President/Head Regenerative Medicine from 2013 to 2014, Senior Vice President, Business and Technical Operations from 2012 to 2013, Senior Vice President, Business and Technical Operations from 2012 to 2013, Global Franchise Head MPS from 2010 to 2012 and as Vice President of Operations/Product General Manager from 2005 to 2012. He served at Shire's Global Franchise Head for a portfolio of biologic products in the rare disease space with sales and operations in over 50 countries. He served as Vice President of Manufacturing of Shire Human Genetic Therapies Inc. since September 2003. Mr. Mohanty was responsible for Shire Human Genetic Therapies Inc. manufacturing operations, which includes the expansion of Shire Human Genetic Therapies Inc.'s manufacturing plant into a multi-product facility. He joined Shire Human Genetic Therapies Inc. in 2002 as Senior Director of Manufacturing, where he played a role in obtaining approval from the European Commission of Shire Human Genetic Therapies Inc.'s manufacturing facility in Cambridge, Massachusetts representing Shire Human Genetic Therapies Inc.'s first cGMP manufacturing facility. He had been a Director of OncoCyte Corporation since April 2015 until June 17, 2020. Mr. Mohanty served as Vice President of Manufacturing and Supply Operations at Transkaryotic Therapies, Inc. from 2002 to 2005. He served a number of engineering and manufacturing positions of increasing responsibility in the Bioscience Division at Baxter Healthcare Corporation from 1990 to 2002. Mr. Mohanty has experience in the biotechnology industry and expertise in business operations and management. He served in various leadership positions of increasing responsibility at Shire plc, including as President/Head of Regenerative Medicine Business from 2013 to 2014, where he oversaw all aspects of that business, including sales and marketing, research and development and manufacturing and led a successful turnaround and divestiture of that business unit. He served as a Director of Asterias Biotherapeutics, Inc. from June 9, 2016 to March 8, 2019. He served as a Director of BioTime, Inc. from March 03, 2016 to September 17, 2018. Mr. Mohanty received an MBA degree from Saint Mary's College, BS and MS degrees in Chemical Engineering from Clarkson University and a B. Tech degree in Chemical Engineering from REC Trichy in India.
Positions
- Company NameBiora Therapeutics, Inc.Stock CodeBIORQPositionCEO & DirectorColleagues
- JDJeffrey Donald AlterIndependent Chairman
- CNClarke NeumannSenior VP, General Counsel & Secretary
- KHKevin HoweSenior VP of Strategic Operations
- PSPaul ShabramHead of Technical Operations
- JKJames KnightHead of Business Development
- BLBrian L. KotzinIndependent Director
- BEBruce E. SandsChairman of Inflammatory Bowel Disease Clinical Advisory Board
- JAJill Ann HoweIndependent Director
